Drugs

, Volume 68, Issue 4, pp 449–459

Nilotinib

Adis Drug Profile

Abstract

  • ▴ Nilotinib is an orally administered BCR-ABL tyrosine kinase inhibitor that has shown good clinical efficacy in imatinib-resistant or -intolerant, Philadelphia chromosome-positive, chronic myeloid leukaemia (CML) in a phase I/II trial. The phase I component of the trial established the dosage regimen used in the phase II part of the trial, which included several arms. Three of these arms, or phase II trials, evaluated nilotinib in each of the three phases of CML (chronic, accelerated or blast crisis).

  • ▴ In the phase II trial in patients with chronic-phase CML, major cytogenetic response (primary endpoint) was achieved in 48% of the 280 patients who received nilotinib and had a follow-up period of ≥6 months. Major cytogenetic response rates did not differ between imatinib-resistant and -intolerant patients, and nilotinib was effective in patients with BCR-ABL mutations (except T315I).

  • ▴ Haematologic response rate (primary endpoint) was 47% in the phase II trial with nilotinib in patients with accelerated-phase CML (n = 119). Complete haematologic response was achieved in 26% of patients and 21% had no evidence of leukaemia or returned to chronic-phase CML. Major cytogenetic response, an important secondary endpoint in the trial, occurred in 29% of patients.

  • ▴ Data from the phase II trial in patients with CML in blast crisis (n = 135) also showed promising results, with 39% of patients achieving haematologic response with nilotinib.

  • ▴ Adverse events reported with nilotinib have generally been of mild to moderate severity. Grade 3 or 4 neutropenia and thrombocytopenia were reported in 29% of patients each.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. V.2.2007 [online]. Available from URL: www.nccn.org/professional/physician-gls/PDF/cml.pdf [Accessed 2007 Apr 23]Google Scholar
  2. 2.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106–30PubMedCrossRefGoogle Scholar
  3. 3.
    Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999 Apr 29; 340(17): 1330–40PubMedCrossRefGoogle Scholar
  4. 4.
    Weisberg E, Manley P, Mestan J, et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006 Jun 19; 94(12): 1765–9PubMedCrossRefGoogle Scholar
  5. 5.
    Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005 Feb; 7(2): 129–41PubMedCrossRefGoogle Scholar
  6. 6.
    Deininger MWN, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003; 55(3): 401–23PubMedCrossRefGoogle Scholar
  7. 7.
    Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006 Dec 7; 355(23): 2408–17PubMedCrossRefGoogle Scholar
  8. 8.
    Moen MD, McKeage K, Plosker GL, et al. Imatinib: a review of its use in chronic myeloid leukaemia. Drugs 2007; 67(2): 299–320PubMedCrossRefGoogle Scholar
  9. 9.
    Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials [abstract no. 23]. Blood 2004 Nov 16; 104(11 Pt 1): 11aGoogle Scholar
  10. 10.
    Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 2006 Feb; 57(2): 145–64PubMedCrossRefGoogle Scholar
  11. 11.
    Druker BJ. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006 Jun 15; 354(24): 2594–6PubMedCrossRefGoogle Scholar
  12. 12.
    O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005 Jun 1; 65(11): 4500–5PubMedCrossRefGoogle Scholar
  13. 13.
    le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000 Mar 1; 95(5): 1758–66PubMedGoogle Scholar
  14. 14.
    Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–6PubMedCrossRefGoogle Scholar
  15. 15.
    Jabbour E, Cortes J, Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias [published erratum appears in Expert Opin Investig Drugs 2007 Jul; 16 (7): 1135]. Expert Opin Investig Drugs 2007 May; 16(5): 679–87PubMedCrossRefGoogle Scholar
  16. 16.
    Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006 Jun 15; 354(24): 2531–41PubMedCrossRefGoogle Scholar
  17. 17.
    Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007 Mar 15; 109(6): 2303–9PubMedCrossRefGoogle Scholar
  18. 18.
    Guilhot F, Apperley J, Kim D-W, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007 May 15; 109(10): 4143–50PubMedCrossRefGoogle Scholar
  19. 19.
    Cortes J, Rousselot P, Kim D-W, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007 Apr 15; 109(8): 3207–13PubMedCrossRefGoogle Scholar
  20. 20.
    Verstovsek S, Golemovic M, Kantarjian H, et al. AMN107, a novel aminopyrimidine inhibitor of pl90 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 2005 Sep 15; 104(6): 1230–6PubMedCrossRefGoogle Scholar
  21. 21.
    Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005 Jul 1; 11(13): 4941–7PubMedCrossRefGoogle Scholar
  22. 22.
    Manley PW, Mestan J, Cowan-Jacob S, et al. AMN107: inhibitory profile against non-mutated and mutated forms of the Bcr-Abl tyrosine kinase [abstract no. 5985]. Presented at the 96th Annual Meeting of the American Association for Cancer Research; 2005 Apr 16–20; Anaheim (CA)Google Scholar
  23. 23.
    Mueller MC, Branford S, Radich J, et al. Response dynamics to nilotinib depend on the type of BCR-ABL mutations in patients with chronic myelogenous leukemia (CML) after imatinib failure [abstract no. 7024]. Plus poster presented at the 43rd Annual Meeting of the American Society of Clinical Oncology; 2007 Jun 1–5; Chicago (IL)Google Scholar
  24. 24.
    Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006 Jun 15; 354(24): 2542–51PubMedCrossRefGoogle Scholar
  25. 25.
    Kagan M, Tran P, Fischer V, et al. Safety, pharmacokinetics, metabolism, and mass balance of [14C]-AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl tyrosine kinase, in healthy subjects [abstract no. 4887]. Blood 2005 Nov 16; 106(11 Pt 2): 302bGoogle Scholar
  26. 26.
    Tanaka C, Smith T, Kantarjian H, et al. Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, in healthy subjects and patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed/refractory Ph+ acute lymphocytic leukemia (Ph+ ALL) [abstract no. 3095]. J Clin Oncol 2006 Jun 20; (18 Pt 1 Suppl. 24): 144sGoogle Scholar
  27. 27.
    Novartis Pharmaceuticals Corporation: East Hanover (NJ). Tasigna® (nilotinib capsules): US prescribing information [online]. Available from URL: http://www.fda.gov/ [Accessed 2007 Nov 29]
  28. 28.
    Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007 Nov 15; 110(10): 3540–6PubMedCrossRefGoogle Scholar
  29. 29.
    le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated phase chronic myelogenous leukemia. Blood 2008 Feb 15; 111(4): 1834–9PubMedCrossRefGoogle Scholar
  30. 30.
    Ottmann O, Larson R, Kantarjian H, et al. Nilotinib monotherapy in patients with imatinib-resistant or -intolerant Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL) [abstract no. 0556]. Plus poster presented at the 12th Congress of the European Hematology Association (EHA); 2007 Jun 7–10; ViennaGoogle Scholar
  31. 31.
    Giles F, le Coutre P, Bhalla K, et al. Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic phase and accelerated phase Philadelphia-positive chronic myelogenous leukemia [abstract no. 0554]. Plus poster presented at the 12th Congress of the European Hematology Association (EHA); 2007 Jun 7–10; ViennaGoogle Scholar
  32. 32.
    Giles FJ, le Coutre P, Bhalla K, et al. A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib [abstract no. 7038]. Plus poster presented at the 43rd Annual Meeting of the American Society of Clinical Oncology; 2007 Jun 1–5; Chicago (IL)Google Scholar
  33. 33.
    Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002 May 15; 99(10): 3547–53PubMedCrossRefGoogle Scholar
  34. 34.
    Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002 Feb 28; 346(9): 645–52PubMedCrossRefGoogle Scholar
  35. 35.
    Singer JB, Shou Y, Giles F, et al. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 2007 Nov; 21(11): 2311–5PubMedCrossRefGoogle Scholar
  36. 36.
    Bristol-Myers Squibb: Princeton (NJ). Sprycel® (dasatinib): US prescribing information, [online]. Available from URL: http://www.fda.gov [Accessed 2007 Dec 6]

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Wolters Kluwer Health ¦ AdisMairangi Bay, North Shore, AucklandNew Zealand
  2. 2.Wolters Kluwer HealthConshohockenUSA

Personalised recommendations